KRAS (G12D)‑selective inhibitor MRTX1133 suppresses proliferation and differentially modulates chemosensitivity in ovarian mucinous carcinoma
Oncology Letters · 15.04.2026 · 31 (6) · 1-9
DOI: 10.3892/ol.2026.15594 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Letters, online erschienen am 15.04.2026. Verfasst von Ryota Watano und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Genetic Therapeutics, Center for Molecular Medicine, Jichi Medical University, Shimotsuke, Tochigi 329-0498, Japan. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Ovarian mucinous carcinoma (OMC) is a rare subtype of ovarian cancer characterized by frequent KRAS mutations and a poor response to platinum- and taxane-based chemotherapy, underscoring the need for novel therapeutic strategies. MRTX1133, a recently developed non-covalent and selective KRAS (G12D) inhibitor, has demonstrated potent antitumor activity in pancreatic and colorectal cancers; however, its efficacy in OMC remains unexplored. In the present study, the antitumor effects of MRTX1133 in the KRAS (G12D)-mutant OMC cell line MCAS and its interactions with conventional chemotherapeutic agents were evaluated. Cell viability was assessed using WST-1 assays, ERK phosphorylation was evaluated by western blotting and gene expression levels were analyzed by reverse transcription-quantitative PCR. Results indicated that MRTX1133 suppressed MCAS cell proliferation in a concentration-dependent manner, whereas proliferation of KRAS wild-type and KRAS (G12S)-mutant cells was not significantly inhibited. Treatment markedly inhibited ERK phosphorylation, suggesting suppression of the MAPK pathway. MRTX1133 reduced the mRNA expression of Ki-67 and numerous cyclins (D1, A2 and B1), suggesting attenuation of proliferative signaling. When combined with cytotoxic agents, including paclitaxel, SN38, gemcitabine and cisplatin, MRTX1133 reduced the sensitivity to cell cycle-dependent chemotherapeutic agents, namely paclitaxel, SN38 and gemcitabine, while not affecting the activity of the non-cell cycle-dependent agent cisplatin. The present study therefore provided preclinical evidence for the potential utility of KRAS (G12D)-targeted therapy in OMC and highlights the importance of sequential rather than concurrent scheduling of MRTX1133 with cell cycle-dependent chemotherapy to optimize therapeutic efficacy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Genetic Therapeutics, Center for Molecular Medicine, Jichi Medical University, Shimotsuke, Tochigi 329-0498, Japan.
- Department of Obstetrics and Gynecology, School of Medicine, Jichi Medical University, Shimotsuke, Tochigi 329-0498, Japan.
Zitieren
APA
Watano, R., Mizukami, H., & Saga, Y. (2026). KRAS (G12D)‑selective inhibitor MRTX1133 suppresses proliferation and differentially modulates chemosensitivity in ovarian mucinous carcinoma. Oncology Letters, 31(6), 1-9. https://doi.org/10.3892/ol.2026.15594
Vancouver
Watano R, Mizukami H, Saga Y. KRAS (G12D)‑selective inhibitor MRTX1133 suppresses proliferation and differentially modulates chemosensitivity in ovarian mucinous carcinoma. Oncology Letters. 2026;31(6):1-9. doi:10.3892/ol.2026.15594
BibTeX
@article{Watano2026,
author = {Watano, Ryota and Mizukami, Hiroaki and Saga, Yasushi},
title = {KRAS (G12D)‑selective inhibitor MRTX1133 suppresses proliferation and differentially modulates chemosensitivity in ovarian mucinous carcinoma},
journal = {Oncology Letters},
year = {2026},
volume = {31},
number = {6},
pages = {1--9},
doi = {10.3892/ol.2026.15594}
}
EUVIMED